Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399137 | 1.00 | POLB (0.39) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL3879963 | 0.96 | POLB (0.39) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL2778858 | 0.95 | POLB (0.35) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL29399534 | 0.95 | POLB (0.35) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL8397404 | 0.90 | TDP1 (0.37) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL25282759 | 0.90 | POLB (0.32) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL30887119 | 0.90 | POLB (0.36) | POLBAPEX1HTTTDP1CA1 | |
| SCHEMBL19252768 | 0.90 | TDP1 (0.39) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL1855363 | 0.90 | HSP90AB1 (0.34) | POLBAPEX1HTTTDP1MAPT | |
| SCHEMBL30602832 | 0.89 | POLB (0.36) | POLBAPEX1HTTTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109119-A1 | STABILIZED FORMULATIONS FOR CONTACT LENSES | COOPERVISION INTERNATIONAL LIMITED (GB) | 2026-04-23 | — | — | US | claimed |
| US-12577345-B2 | Radiation blockers for contact lenses | COOPERVISION INTERNATIONAL LIMITED (GB) | 2026-03-17 | — | — | US | claimed |
| US-20250109234-A1 | RADIATION BLOCKERS FOR CONTACT LENSES | COOPERVISION INTERNATIONAL LIMITED (GB) | 2025-04-03 | — | — | US | claimed |
| US-11926689-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2024-03-12 | — | — | US | claimed |
| US-20240018309-A1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2024-01-18 | — | — | US | claimed |
| WO-2023228055-A1 | UV/HEVL-FILTERING CONTACT LENSES | ALCON INC. (CH) | 2023-11-30 | — | — | WO | claimed |
| US-20230374306-A1 | UV/HEVL-FILTERING CONTACT LENSES | ALCON INC. (CH) | 2023-11-23 | — | — | US | claimed |
| US-20230364832-A1 | METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES | ALCON INC. (CH) | 2023-11-16 | — | — | US | claimed |
| WO-2023209631-A1 | METHOD FOR MAKING UV AND HEVL-ABSORBING OPHTHALMIC LENSES | ALCON INC. (CH) | 2023-11-02 | — | — | WO | claimed |
| US-11802182-B2 | Silicone hydrogel contact lenses | ALCON INC. (CH) | 2023-10-31 | — | — | US | claimed |
| US-20030223954-A1 | Polymeric materials for use as photoablatable inlays | BAUSCH & LOMB INCORPORATED | 2003-12-04 | — | — | US | claimed |
| US-6657029-B2 | High refractive index monomer, greater amount of a hydrophilic monomer, crosslinker, and initiator; give water content; intraocular lenses | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-6657032-B2 | High refractive index and hydrophilic monomers, a crosslinker, an initiator and water | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | claimed |
| US-20020049290-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-25 | — | — | US | claimed |
| US-20020042483-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-11 | — | — | US | claimed |
| US-20020042484-A1 | High refractive index hydrogel compositions for ophthalmic implants | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2002-04-11 | — | — | US | claimed |
| US-20020037984-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-03-28 | — | — | US | claimed |
| US-6329485-B1 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2001-12-11 | — | — | US | claimed |
| WO-2000079312-A1 | HIGH REFRACTIVE INDEX COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-12-28 | — | — | WO | claimed |
| US-4716234-A | Ultraviolet absorbing polymers comprising 2-(2'-hydroxy-5'-acryloyloxyalkoxyphenyl)-2H-benzotriazole | IOLAB CORPORATION (US) | 1987-12-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577345-B2 | Radiation blockers for contact lenses | TBL3, TTLL12, TBL2 | POLB 2675/4885APEX1 4039/4885HTT 58/4885 |
| US-20260109119-A1 | STABILIZED FORMULATIONS FOR CONTACT LENSES | POT1, TELO2, TST | POLB 3333/4885APEX1 1527/4885HTT 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.